This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally.View CTIC
CTI BioPharma Corp. - CTIC - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates CTI BioPharma Corp. as a
Sell with a ratings score of E+.
Report Snippet: We rate CTI BIOPHARMA CORP (CTIC) a SELL. This is based on a variety of negative investment measures, which should drive this stock to significantly underperform the majority of stocks that we rate. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow and generally disappointing historical performance in the stock itself.